Elanco's Canine Parvovirus Treatment Gets USDA License

RTTNews | Pred 532 dňami

(RTTNews) - Elanco Animal Health Inc. announced that the U.S. Department of Agriculture or USDA has issued a conditional license for its Canine Parvovirus Monoclonal Antibody.

The company expects to begin shipping Canine Parvovirus Monoclonal Antibody in the coming weeks, pending individual state approvals.

The targeted single-dose monoclonal antibody is the first and only approved targeted therapeutic solution proven to treat deadly dog disease. The conditional license approval was granted by the USDA to effectively and safely meet an emergency situation, limited market or special circumstance.

It is the first monoclonal antibody for Elanco, which recently received the U.S. Food and Drug Administration's conditional approval for its Varenzin-CA1 to treat anemia in cats with chronic kidney disease.

The USDA conditional license is based on clinical trials that demonstrate the Canine Parvovirus Monoclonal Antibody single, intravenous dose delivers targeted efficacy in treating canine parvovirus.

In the treatment efficacy study, the Canine Parvovirus Monoclonal Antibody was proven effective in decreasing mortality associated with parvovirus infection.

The company noted that the treatment can be administered to dogs eight weeks of age or older with canine parvovirus. According to the firm, the treatment may provide a less intensive and more effective solution than supportive care alone by targeting the virus with single dose efficacy and a strong safety profile in healthy dogs.

Elanco will also continue to provide canine parvovirus education and resources to veterinarians, shelter owners and pet parents.

Canine parvovirus is one of the most contagious and deadly viruses a dog can contract with a 91 percent mortality rate if not treated with supportive care. Annually, an estimated 330,000 cases of canine parvovirus are reported for treatment in the U.S. Prior to Elanco's Canine Parvovirus Monoclonal Antibody, the only treatment for the highly contagious canine parvovirus was supportive therapy, which can consist of 24/7 care and multi-day hospitalization.

Kristin Zersen, assistant professor of small animal emergency and critical care at Colorado State University Veterinary Teaching Hospital, said, "Parvovirus is an unpredictable disease that causes significant strain on pet owners and is labor intensive and stressful for shelters and veterinary clinic staff. It's lifechanging and industry-defining to be able to offer a proven solution to canine parvovirus that limits the need for hospitalization, reducing the impact this disease has on hundreds of thousands of dogs each year."

For More Such Health News, visit rttnews.com

Značky: ELAN

Elanco Animal Health Closes Sale Of Aqua Business To Merck Animal Health

Elanco Animal Health, Inc. (ELAN) announced Tuesday it has completed the divestiture of its aqua business to Merck Animal Health (MRK) for approximately $1.3 billion in cash, with approximately $1.05 billion to $1.1 billion in net proceeds available for debt paydown in the third quarter of 2024.

RTTNews | Pred 99 dňami

Elanco Animal Health Boosts FY23 Adj. EPS, Revenue Outlook As Q3 Results Top Estimates

Elanco Animal Health Inc. (ELAN) reported Tuesday a net loss for the third quarter of $1.10 billion or $2.22 per share, sharply wider than $65.0 million or $0.13 per share in the prior-year quarter.

RTTNews | Pred 344 dňami

FDA Approves First Drug For Anemia In Cats With CKD

The U.S. Food and Drug Administration conditionally approved Elanco US Inc.'s Varenzin-CA1 (molidustat oral suspension) for treating anemia in cats with chronic kidney disease or CKD. It is the first drug for the control of nonregenerative anemia associated with CKD in cats. Varenzin-CA1 works by helping to increase production of erythropoietin in the kidney, which in turn stimulates the bone mar

RTTNews | Pred 533 dňami

Walgreens To Close 1,200 US Stores

Walgreens announced its plan to close around 1,200 U.S stores over the next three years, including around 500 closures in fiscal 2025, as the drug store chain is facing a challenging U.S. retail environment amid increasing competition. The move, which was announced while reporting a significantly wider net loss in its fourth quarter, is expected to be immediately accretive to adjusted earnings...

RTTNews | Pred 4 h 33 min

U.S. Import Prices Decrease In Line With Estimates In September

Reflecting a sharp drop by prices for fuel imports, the Labor Department released a report on Wednesday showing a continued decrease by prices for U.S. imports in the month of September.

RTTNews | Pred 4 h 51 min

Bank Of Thailand Trims Rate Unexpectedly

The Bank of Thailand unexpectedly lowered its policy interest rate for the first time in more than four years, as inflation is projected to return towards the target range by the end of this year. The Monetary Policy Committee voted 5-2 to cut the policy rate by 25 basis points to 2.25 percent. Two committee members sought to maintain the rate at 2.50 percent.

RTTNews | Pred 4 h 59 min

Bay Street Seen Opening On Mixed Note

Canadian shares are likely to open on a mixed note Wednesday morning, tracking commodity prices. The focus will also be on some key earnings updates from major U.S. companies. Optimism about more interest rate cuts by central banks, including the Federal Reserve and the Bank of Canada may help underpin sentiment.

RTTNews | Pred 5 h 9 min

Sensex, Nifty End Modestly Lower On Weak Global Cues

Indian shares closed lower on Wednesday, with continued foreign fund outflows, reduced bets on larger Fed rate cuts and disappointing earnings updates from the likes of LVMH and ASML Holding weighing on markets.

RTTNews | Pred 7 h 2 min

EURUSD	1.0893	GBPUSD	1.30226	AUDUSD	0.66738
USDJPY	149.338	USDCAD	1.37776	USDCHF	0.86311